The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ace inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function

Summary of AHRQ's Comparative Effectiveness Review of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease

“…44 In 3 trials, no differences across treatment and placebo groups were observed for cough. 40,42,44 No trials addressing this key question reported the incidence of angioedema, syncope, renal impairment, hyperkalemia, rash, or blood dyscrasias.…”

“…[38][39][40][41][42][43][44] One trial initiated therapy 7-10 days before the procedure, 1 initiated therapy at the same time, and the rest initiated therapy within 7 days after revascularization. Across the 7 studies, the majority of participants were males (76%-91%) who had mean left ventricular ejection fractions above 40%; in 6 of the studies, mean ejection fraction was approximately 60%.…”

Review: Angiotensin-converting enzyme inhibitors and coronary heart disease prevention

“…The number of ischaemic events in the quinapril group (338) and the placebo group (329) were similar, relative risk 1.04 (95% CI 0.89-1.22, p=0.6). 12 Similarly, the time to first major cardiac ischaemic event was not significantly different between the two groups. A total of 602 angioplasty procedures were performed during the period of study follow-up: 312 among placebo-treated patients and 290 among quinapril-treated patients.…”

Fixed Combination of Ramipril and Hydrochlorothiazide: To Whom and What For?

“…Очевидно, что решающим в их дифференцированном применении становятся особенности блокатора РААС. Ярким подтверждением существенных различий внутри класса ИАПФ является сравнение результатов исследований по их антиатеросклеротическому дей-ствию -SECURE (рамиприл) [14], QUIET (квина-прил) [15] и SCAT (эналаприл) [16], в которых только рамиприл продемонстрировал способность оказы-вать дозозависимое замедление темпа прогрессиро-вания атеросклеротического процесса. Необходимо понять те исключительные возможности, которые открывает наличие рамиприла в комбинации с ГХТЗ.…”